News
21h
GlobalData on MSNRegeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myelomaRegeneron has won US Food and Drug Administration (FDA) approval for Lynozyfic (linvoseltamab-gcpt), marking the entry of ...
While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...
Regeneron Pharmaceuticals gains FDA approval for Lynozyfic drug targeting multiple myeloma, with launch details and executive ...
The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic™ (linvoseltamab-gcpt) for the treatment of adult patients with ...
Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...
Lynozyfic (linvoseltamab) has been given accelerated approval by the US regulator for adults with relapsed or refractory ...
FDA grants accelerated approval to Regeneron's Lynozyfic for relapsed multiple myeloma after strong results in a Phase 1/2 trial.
The US Food and Drug Administration (FDA) has granted accelerated approval for Regeneron Pharmaceuticals’ Lynozyfic ...
20h
Zacks.com on MSNFDA Grants Accelerated Approval to Regeneron's Blood Cancer DrugREGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.
Kansas City, Kansas, residents are suing Harcros Chemicals, accusing the company of poisoning the air for decades with a “toxic cocktail” of emissions – leading to the deaths of ...
Following its acquisition by Supernus Pharmaceuticals, Sage Therapeutics has let go of all of its remaining workforce, which ...
The keen interest from Big Pharma has also excited the stock market. After the Otsuka deal was announced, HBM's share price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results